AJCC pathological prognostic staging downstaged 74.7 per cent of patients with breast cancer with hormone receptor-positive and HER2-positive disease but does not provide better risk discriminatory ability in predicting prognosis than anatomical staging. The gene discussed is NR4A1; the disease is breast carcinoma.